Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis

Main Article Content

Boni Elewski
Alan Menter
Jeffrey Crowley
Stephen Tyring
Yang Zhao
Simon Lowry
Stephen Rozzo
Alan Mendelsohn
Jeffrey Parno
Kenneth Gordon

Keywords

psoriasis, tildrakizumab

Abstract

Abstract not available.

 

Disclosures: Study sponsored by SUN PHARMA.

 

Copyright SKIN 2018